http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10675291-B2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_00ca6f00ac12fd683f21da5d20c6d349
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56262e82e60ea99a6ed6fba023929546
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5270fe656bc80c670b4e3e83590e0d57
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0029
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61J1-1468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-665
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61J3-002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61J1-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61J1-1412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61J1-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-665
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
filingDate 2017-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2020-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80e2978d5bb363e3d17024bdb6a7349e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_975ecab98e74c49267c96db6009cc0a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df1644244bdf679dbdd1008e076a1525
publicationDate 2020-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-10675291-B2
titleOfInvention Fosfomycin formulation for parenteral administration
abstract The field of the present invention is that of fosfomycin formulations for parenteral administration, in particular for intravenous administration. Formulations of the prior art provide fosfomycin as a powder to be diluted directly prior to the administration. The aim of the invention is to provide a fosfomycin formulation for parenteral administration which is easier to produce and administer or which lowers the risk of puncture injuries for healthcare professionals and the health risks for the patients (for example due to contamination or incorrect dosages) by preventing additional processing steps. During the course of the invention, it was surprisingly shown that fosfomycin is much more stable in an aqueous solution than what is commonly assumed. The invention therefore provides a closed container which contains an aqueous solution for parenteral administration, wherein at least one pharmaceutically acceptable salt of fosfomycin, in particular fosfomycin disodium salt, and a pharmaceutically acceptable acid, in particular succinic acid, are dissolved in the solution. Preferred containers are breakable ampoules made of plastic or glass, puncturable vials, infusion bags, or syringes ready for injection.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10993951-B2
priorityDate 2016-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8980226-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005110022-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015057242-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005014829-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-202008012514-U1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226413684
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226405795
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395180
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID36294
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226446642
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID47641
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID1290
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID1906
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID1290
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6038
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15366
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226413683
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5282481
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3000226
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID53911549
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5984
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2484
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226400426
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID439709
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226423537
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396047
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226422748
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID37768
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226422749
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226397425
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID149096
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396046
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395281
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399773
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226432968
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398631
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID1906
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1549008

Total number of triples: 68.